Chronic wounds cause substantial morbidity and mortality and can lead to significant medical costs. 2 In
The randomised, controlled, multicentre study was conducted at 16 centres in the
A greater average reduction in wound area of 39.1%, depth of 32.5% and volume of 91.1% versus tNPWT was observed with PICO sNPWT. 1 There was a 51% relative increase in the number of patients achieving wound closure at 12 weeks with PICO sNPWT versus tNPWT. Dressing changes were less frequent with PICO sNPWT than with tNPWT, mean reported 6.8 fewer changes and 3.4 days longer wear time. Overall satisfaction was also greater with PICO sNPWT, and fewer patients had adverse events with PICO sNPWT than with tNPWT.
'I decided to use PICO Single Use Negative Pressure Wound Therapy System to treat a diabetic foot ulcer, after achieving excellent results using the therapy on skin flaps and full thickness skin grafts' s aid,
The unique PICO sNPWT dressing includes the proprietary AIRLOCK Technology for uniform and consistent delivery of therapeutic NPWT across a wound and the surrounding zone of injury. 7 By minimising the need for fillers and reducing dressing change frequency compared with traditional NPWT 1, PICO sNPWT helps healing to progress undisturbed, contributing to faster time to healing, improved quality and distribution of granulation tissue and more consistent re-epithelialisation. 8
PICO sNPWT has a strong evidence base with 103 published papers of which 21 are published RCTs and 65 are unique clinical studies. 1,9
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 16,000+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the
Contact:
Tel: +1 (978) 749-1440
(C) 2020 Electronic News Publishing, source